Related Experiment Video
Updated: Apr 30, 2026
Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity
Published on: March 31, 2023
Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis
11] Division of Nephrology, Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, Ontario, Canada L8S 4L8 [2] Father Sean O'Sullivan Research Centre, St. Joseph's Healthcare Hamilton, 50 Charlton Avenue East, Hamilton, Ontario, Canada L8N 4A6 [3] The Hamilton Center for Kidney Research, St. Joseph's Healthcare Hamilton, 50 Charlton Avenue East, Hamilton, Ontario, Canada L8N 4A6.
Aldehyde dehydrogenase 3A1 (ALDH3A1) is significantly upregulated in prostate cancer (PC) stem cells and metastatic tumors. This finding suggests ALDH3A1 is a potential biomarker for advanced prostate cancer progression.
Area of Science:
- Oncology
- Biochemistry
Background:
- Aldehyde dehydrogenase (ALDH) activity is linked to cancer stem cells across various human cancers.
- While ALDH1A1 and ALDH7A1 are implicated in prostate cancer (PC), the role of other ALDH isoforms remains largely unknown.
Purpose of the Study:
- To investigate the association of aldehyde dehydrogenase 3A1 (ALDH3A1) with prostate cancer progression.
- To determine ALDH3A1 expression levels in PC cell lines, xenografts, and human PC tissues.
Main Methods:
- Analyzed ALDH3A1 expression in PC cell lines.
- Utilized immunohistochemistry to assess ALDH3A1 in xenograft tumors and 54 primary/metastatic PC samples.
Main Results:
- ALDH3A1 was robustly upregulated in PC stem cells (PCSCs) compared to non-stem cells.
- ALDH3A1 expression increased with tumor aggressiveness, notably in lung and lymph node metastases.
- ALDH3A1 was detected in prostatic intraepithelial neoplasia (PIN) and carcinomas, with higher levels in metastatic tissues.
Conclusions:
- ALDH3A1 expression is associated with prostate cancer progression.
- ALDH3A1 may serve as a biomarker for advanced PC and metastasis.
